In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

A man who says he got 'Ozempic penis' from the weight loss drug Wegovy has opened up on how his sex life has been going ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Shares of Novo Nordisk climbed 4.29% during Friday’s pre-market trading session, after rival Eli Lilly’s Phase 3 ATTAIN-1 ...

The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

Novo Nordisk shares jumped more than 5% on Friday, extending Thursday’s rally, after Eli Lilly’s obesity pill data fell short of market expectations.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

European stocks edged higher on Friday, led by upbeat corporate earnings and a jump in Novo Nordisk shares, and were set for ...

European shares edged higher and were on track for their biggest weekly gain in 12 as investors assessed U.S. President ...

The mini tender offer is for the purchase of up to 2 million American Depositary shares representing less than 0.045% of its ...

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...